pharma · Glioblastoma · Unresectable or metastatic soft tissue sarcoma
Philogen
Philogen S.p.A.
Philogen clinical programs — 9 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Loc. Bellaria, 35, Sovicille, SIENA 53018, IT
- Founded
- 1996
- Employees
- 180
- Programs
- 18
- Drugs
- 29
- Patents
- 0
Philogen projects
9 ClinicalTrials.gov programs sponsored by Philogen.
Philogen has 9 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Darleukin, Fibromun
Philogen S.p.A.
Patients with high-risk, locally advanced (non-metastatic, node negative, single or multifocal), Basal Cell Carcinoma (BCC) or cutaneous Squamous Cell Carcinoma (cSCC) amenable to intratumoral injection, not eligible to surgery or radiation therapy according to the evaluation of a local interdisciplinary tumor board or who refuse surgery or radiation therapy and for whom a histological evaluation is available according to international guidelines.
1 trial -
Darleukin, Fibromun
Philogen S.p.A.
locally advanced basal cell carcinoma patients
1 trial -
Fibromun, Darleukin
Philogen S.p.A.
Cutaneous Squamous Cell Carcinoma
1 trial -
Fibromun, Darleukin
Philogen S.p.A.
Phase II, open label, multicentric, proof-of-principle basket trial in patients with malignant tumors of the skin amenable to intratumoral injection, and in a curative or neoadjuvant or palliative intention, including: • Basal cell carcinoma (BCC) • Cutaneous squamous cell carcinoma (cSCC) • Merkel cell carcinoma (MCC) • Keratoacanthoma (KA) • Malignant adnexal tumors of the skin (MATS) • Tumors from cutaneous T-cell lymphoma (CTCL) • Kaposi’s sarcoma (KS)
1 trial -
Fibromun, Darleukin
Philogen S.p.A.
Patients with locally advanced Basal Cell Carcinoma (LaBCC) amenable to intratumoral injection, who have progressed or intolerant to systemic treatment.
1 trial -
Fibromun, Temozolomide SUN 100 mg hard capsules
Philogen S.p.A.
Glioblastoma
1 trial -
Lomustine "medac" 40 mg, Fibromun
Philogen S.p.A.
Glioblastoma
1 trial -
PH-ICKPD1-02/21
Philogen S.p.A.
Patients with diagnosis of unresectable clinical stage III or IV metastatic melanoma, with presence of injectable cutaneous, subcutaneous or nodal lesions and resistant to or progressing upon anti-PD1 immunotherapy
1 trial -
PH-L19TNFSARC-03/18
Philogen S.p.A.
Unresectable and/or metastatic soft-tissue sarcoma after failure of at least two prior systemic therapy regimens.
1 trial
Frequently asked questions
How many clinical projects does Philogen have?
9 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.